Appendix 1—table 1. Studies used for derivation of pathological markers of immunotherapy response.

Reference (see main text)	Tumor type	Checkpoint inhibitor	Pathological biomarker	PD-L1 staining cutoff
Tumeh et al., 2014	Melanoma	Pembrolizumab	CD8+ TILs	N/A
Kefford et al., 2014	Melanoma	Pembrolizumab	PD-L1	1%
Powles et al., 2014	UCC	Atezolizumab	PD-L1	1%, 5%, 10%
Herbst et al., 2014	NSCLC, RCC, melanoma, HNSCC, CRC, gastric and pancreatic cancer	Atezolizumab	PD-L1	1%, 5%, 10%
Robert et al., 2015b	Melanoma	Nivolumab	PD-L1	5%
Motzer et al., 2015	RCC	Nivolumab	PD-L1	5%
Taube et al., 2014	NSCLC, RCC, melanoma, PC, CRC	Nivolumab	PD-L1	5%
Spira et al., 2015	NSCLC	Atezolizumab	PD-L1	1%, 5%, 10%
Brahmer et al., 2012	NSCLC	Nivolumab	PD-L1	1%, 5%, 10%
Borghaei et al., 2015	NSCLC	Nivolumab	PD-L1	1%, 5%, 10%
Weber et al., 2015	Melanoma	Nivolumab	PD-L1	5%
Topalian et al., 2012	Melanoma, RCC, NSCLC, CRC, PC	Nivolumab	PD-L1	5%
Garon et al., 2015	NSCLC	Pembrolizumab	PD-L1	1%, 50%

RCC: renal cell; UCC: urothelial cell carcinoma; CRC: colorectal carcinoma; NSCLC: non-small lung carcinoma; HNSCC: head and neck squamous cell carcinoma; PC: prostate carcinoma; TIL: tumor-infiltrating lymphocytes.